SRT 2183


Cat. No.:	HY-19759				
CAS No.:	1001908-89-9				
Molecular Formula:	C ₂₇ H ₂₄ N ₄ O ₂ S				
Molecular Weight:	468.57				
Target:	Sirtuin; Apoptosis				
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	2 years		
		-20°C	1 year		

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1342 mL	10.6708 mL	21.3415 mL	
		5 mM	0.4268 mL	2.1342 mL	4.2683 mL
	10 mM	0.2134 mL	1.0671 mL	2.1342 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.		
n Vivo	1. Add each solvent	one by one: 10% DMSO >> 40% PE(G300 >> 5% Tween-8	0 >> 45% saline	
	mg/mL (4.44 mM); Clear solution				

BIOLOGICAL ACTIV	
DIOLOGICALACTIV	
Description	SRT 2183 is a selective Sirtuin-1 (SIRT1) activator with an EC _{1.5} value of 0.36 μM ^[1] . SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels ^[2] .
IC ₅₀ & Target	SIRT1 0.36 μM (EC1.5)
In Vitro	SRT 2183 (1-10 μM; 24-72 hours) inhibits the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner ^[2] . SRT 2183 (5-10 μM in Reh cells; 10 μM in Ly3 cells; 24 hours) induces expression of DNA-damage response genes associated with accumulation of phospho-H2A.X levels ^[2] . SRT2183 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.





Product Data Sheet

Cell Line:	Reh cells, Nalm-6 cells (pre-B acute lymphoblastic leukemia (ALL) cell lines)
Concentration:	1 μΜ, 5 μΜ, 10 μΜ
Incubation Time:	24 hours, 48 hours, 72 hours
Result:	Inhibited the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner. The IC ₅₀ (median inhibition concentration) values for SRT 2183-mediated inhibition of proliferation at 48 h are approximately 8.7 μM for Reh cells and approximately 3.2 μM for Nalm-6 cells.
Western Blot Analysis ^[2]	
Cell Line:	Reh cells, Ly3 cells
Concentration:	5μM and 10μM (Reh cells); 10μM (Ly3 cells)
Incubation Time:	24 hours
Result:	Induced accumulation of phospho-H2A.X in Reh as well as in Ly3 cells.

CUSTOMER VALIDATION

- Aging. 2020 Nov 20;12(23):24208-24218.
- J BUON. Nov-Dec 2020;25(6):2665-2671.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29; 450(7170): 712–716.

[2]. Scuto A, et al. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis. 2013 May; 4(5): e635.

[3]. Gurt I, et al. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA